


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of			) MAIL STOP MISSING PARTS			
Jaan PALGI et al.			) Confirmation No.: 5095			
Applic	cation l	No.: 10/583,329	)			
Filing	Date:	June 16, 2006	)			
Title:	BRO REG POL AND	LEIC ACID PROBES AND PAD-RANGE PRIMERS FROM BIONS IN DNA DIRECTED RNA YMERASE SUBUNIT B GENES, METHODS IN WHICH THEY USED	) ) ) )			
		TRANSMITTAL LETTER FOR	R NOTICE TO COMPLY			
P.O. I	3ox 14	ner for Patents 50 VA 22313-1450	. *			
Sir:						
Conta	ining 1	response to the Notice to Comply witl Nucleotide and/or Amino Acid Sequen ease find:	n Requirements for Patent Applications ce Disclosures dated <u>April 10, 2007</u> ,			
$\boxtimes$	a Co	a Combined Declaration and Power of Attorney signed by the inventor(s);				
		and Power of Attorney is different the < <or>&gt; Note that the inventors iden</or>	ne concurrently filed Combined Declaration an listed on the application filing papers. ntified on the currently filed Combined re different than listed on the application			
	an A	an Application Data Sheet < <or>&gt;&gt; a Supplemental Application Data Sheet;</or>				
	the surcharge of \$\Bigcup \$65 \$\Bigcup \$130 as set forth in 37 C.F.R. \§ 1.16(f);					
	a Request for Refund;					
	a Petition for Extension of Time;					
	a verified English translation of the application, and the 130 fee as set forth in 37 C.F.R. § 1.17(k);					
	drawings for publication;					
П	an Information Disclosure Statement:					

Transmittal Letter for Missing Parts of Application Application No.. 10/583,329
Attorney Docket No. 1034456-000037
Page 2

	a certified copy of the priority document < <or>&gt; certified copies of the priority documents;</or>				
$\boxtimes$	copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures; and				
$\boxtimes$	Declaration Under 37 CFR 1.821-825; Sequence Listing (paper copy); Sequence Listing (diskette).				
	Small entity status is hereby claimed.				
	Charge to Deposit Account No. 02-4800 for the fee due.				
	A check in the amount of is enclosed for the fee due.				
	Charge to credit card for the fee due. Form PTO-2038 is attached.				
	The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.				
	Respectfully submitted,				
	BUCHANAN INGERSOLL & ROONEY PC				
Date	June 7, 2007  By:   By:   Lisa E. Stahl  Registration No. 56,704				

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620



## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

The listing Duty 6-10-0"

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <a href="https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html">https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</a>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <a href="http://www.uspto.gov/ebc.">http://www.uspto.gov/ebc.</a>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.				
10/583,329	PCT/FI04/00776	1034456-000037				

FORM PCT/DO/EO/922 (371 Formalities Notice)